Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T 

Diabetic Retinopathy Clinical Research Network

Research output: Contribution to journalArticle

Abstract

Purpose: Assess associations of 2-year visual acuity (VA) outcomes with VA and optical coherence tomography central subfield thickness (CST) after 12 weeks of anti–vascular endothelial growth factor treatment for diabetic macular edema in DRCR.net Protocol T. Design: Randomized clinical trial. Methods: SETTING: Multicenter (89 U.S. sites). PATIENT POPULATION: Eyes with VA and CST data from baseline and 12-week visits (616 of 660 eyes randomized [93.3%]). INTERVENTION: Six monthly injections of 2.0 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab; subsequent injections and focal/grid laser as needed for stability. MAIN OUTCOME MEASURES: Change in VA from baseline and VA letter score at 2 years. Results: Twelve-week VA response was associated with 2-year change in VA and 2-year VA letter score for each drug (P <.001) but with substantial individual variability (multivariable R2 = 0.38, 0.29, and 0.26 for 2-year change with aflibercept, bevacizumab, and ranibizumab, respectively). Among eyes with less than 5-letter gain at 12 weeks, the percentages of eyes gaining 10 or more letters from baseline at 2 years were 42% (20 of 48), 31% (21 of 68), and 47% (28 of 59), and median 2-year VA was 20/32, 20/32, and 20/25, in the aflibercept, bevacizumab, and ranibizumab groups, respectively. Twelve-week CST response was not strongly associated with 2-year outcomes. Conclusions: A suboptimal response at 12 weeks did not preclude meaningful vision improvement (ie, ≥ 10-letter gain) in many eyes at 2 years. Eyes with less than 5-letter gain at 12 weeks often had good VA at 2 years without switching therapies.

Original languageEnglish (US)
Pages (from-to)93-100
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume195
DOIs
StatePublished - Nov 1 2018

Fingerprint

Endothelial Growth Factors
Macular Edema
Visual Acuity
Injections
Optical Coherence Tomography
Lasers
Randomized Controlled Trials

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T . / Diabetic Retinopathy Clinical Research Network.

In: American Journal of Ophthalmology, Vol. 195, 01.11.2018, p. 93-100.

Research output: Contribution to journalArticle

@article{4e6debfd3a10446f9b50ff0444f3e23f,
title = "Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T ",
abstract = "Purpose: Assess associations of 2-year visual acuity (VA) outcomes with VA and optical coherence tomography central subfield thickness (CST) after 12 weeks of anti–vascular endothelial growth factor treatment for diabetic macular edema in DRCR.net Protocol T. Design: Randomized clinical trial. Methods: SETTING: Multicenter (89 U.S. sites). PATIENT POPULATION: Eyes with VA and CST data from baseline and 12-week visits (616 of 660 eyes randomized [93.3{\%}]). INTERVENTION: Six monthly injections of 2.0 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab; subsequent injections and focal/grid laser as needed for stability. MAIN OUTCOME MEASURES: Change in VA from baseline and VA letter score at 2 years. Results: Twelve-week VA response was associated with 2-year change in VA and 2-year VA letter score for each drug (P <.001) but with substantial individual variability (multivariable R2 = 0.38, 0.29, and 0.26 for 2-year change with aflibercept, bevacizumab, and ranibizumab, respectively). Among eyes with less than 5-letter gain at 12 weeks, the percentages of eyes gaining 10 or more letters from baseline at 2 years were 42{\%} (20 of 48), 31{\%} (21 of 68), and 47{\%} (28 of 59), and median 2-year VA was 20/32, 20/32, and 20/25, in the aflibercept, bevacizumab, and ranibizumab groups, respectively. Twelve-week CST response was not strongly associated with 2-year outcomes. Conclusions: A suboptimal response at 12 weeks did not preclude meaningful vision improvement (ie, ≥ 10-letter gain) in many eyes at 2 years. Eyes with less than 5-letter gain at 12 weeks often had good VA at 2 years without switching therapies.",
author = "{Diabetic Retinopathy Clinical Research Network} and Bressler, {Neil M} and Beaulieu, {Wesley T.} and Maguire, {Maureen G.} and Glassman, {Adam R.} and Blinder, {Kevin J.} and Bressler, {Susan B} and Gonzalez, {Victor H.} and Jampol, {Lee M.} and Michele Melia and Sun, {Jennifer K.} and Wells, {John A.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ajo.2018.07.030",
language = "English (US)",
volume = "195",
pages = "93--100",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T 

AU - Diabetic Retinopathy Clinical Research Network

AU - Bressler, Neil M

AU - Beaulieu, Wesley T.

AU - Maguire, Maureen G.

AU - Glassman, Adam R.

AU - Blinder, Kevin J.

AU - Bressler, Susan B

AU - Gonzalez, Victor H.

AU - Jampol, Lee M.

AU - Melia, Michele

AU - Sun, Jennifer K.

AU - Wells, John A.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Purpose: Assess associations of 2-year visual acuity (VA) outcomes with VA and optical coherence tomography central subfield thickness (CST) after 12 weeks of anti–vascular endothelial growth factor treatment for diabetic macular edema in DRCR.net Protocol T. Design: Randomized clinical trial. Methods: SETTING: Multicenter (89 U.S. sites). PATIENT POPULATION: Eyes with VA and CST data from baseline and 12-week visits (616 of 660 eyes randomized [93.3%]). INTERVENTION: Six monthly injections of 2.0 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab; subsequent injections and focal/grid laser as needed for stability. MAIN OUTCOME MEASURES: Change in VA from baseline and VA letter score at 2 years. Results: Twelve-week VA response was associated with 2-year change in VA and 2-year VA letter score for each drug (P <.001) but with substantial individual variability (multivariable R2 = 0.38, 0.29, and 0.26 for 2-year change with aflibercept, bevacizumab, and ranibizumab, respectively). Among eyes with less than 5-letter gain at 12 weeks, the percentages of eyes gaining 10 or more letters from baseline at 2 years were 42% (20 of 48), 31% (21 of 68), and 47% (28 of 59), and median 2-year VA was 20/32, 20/32, and 20/25, in the aflibercept, bevacizumab, and ranibizumab groups, respectively. Twelve-week CST response was not strongly associated with 2-year outcomes. Conclusions: A suboptimal response at 12 weeks did not preclude meaningful vision improvement (ie, ≥ 10-letter gain) in many eyes at 2 years. Eyes with less than 5-letter gain at 12 weeks often had good VA at 2 years without switching therapies.

AB - Purpose: Assess associations of 2-year visual acuity (VA) outcomes with VA and optical coherence tomography central subfield thickness (CST) after 12 weeks of anti–vascular endothelial growth factor treatment for diabetic macular edema in DRCR.net Protocol T. Design: Randomized clinical trial. Methods: SETTING: Multicenter (89 U.S. sites). PATIENT POPULATION: Eyes with VA and CST data from baseline and 12-week visits (616 of 660 eyes randomized [93.3%]). INTERVENTION: Six monthly injections of 2.0 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab; subsequent injections and focal/grid laser as needed for stability. MAIN OUTCOME MEASURES: Change in VA from baseline and VA letter score at 2 years. Results: Twelve-week VA response was associated with 2-year change in VA and 2-year VA letter score for each drug (P <.001) but with substantial individual variability (multivariable R2 = 0.38, 0.29, and 0.26 for 2-year change with aflibercept, bevacizumab, and ranibizumab, respectively). Among eyes with less than 5-letter gain at 12 weeks, the percentages of eyes gaining 10 or more letters from baseline at 2 years were 42% (20 of 48), 31% (21 of 68), and 47% (28 of 59), and median 2-year VA was 20/32, 20/32, and 20/25, in the aflibercept, bevacizumab, and ranibizumab groups, respectively. Twelve-week CST response was not strongly associated with 2-year outcomes. Conclusions: A suboptimal response at 12 weeks did not preclude meaningful vision improvement (ie, ≥ 10-letter gain) in many eyes at 2 years. Eyes with less than 5-letter gain at 12 weeks often had good VA at 2 years without switching therapies.

UR - http://www.scopus.com/inward/record.url?scp=85052868070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052868070&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2018.07.030

DO - 10.1016/j.ajo.2018.07.030

M3 - Article

C2 - 30077569

AN - SCOPUS:85052868070

VL - 195

SP - 93

EP - 100

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -